Skip to content
Screener

Accounts Payable at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.16B-23.4%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$50.98M-62.7%
Cytokinetics logo
CytokineticsCYTK
$20.51M+26.4%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$313.05M-1.5%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$10.78M+53.6%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$4.36M-7.3%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.78B+236%
Enterprise value$4.75B+244%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
AssetsAs of / March 31, 2026 / (unaudited)As of / December 31, 2025
Total assets$518,522$552,603
Liabilities and stockholders' equity
Current liabilities
Accounts payable$7,293$6,006
Accrued compensation5,67812,430
Accrued other expenses8,5557,920
Operating lease liability, current portion1,0171,014
Total current liabilities22,54327,370

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s accounts payable?
Edgewise Therapeutics, Inc. (EWTX) reported accounts payable of $7.29M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s accounts payable changed year-over-year?
Edgewise Therapeutics, Inc.'s accounts payable decreased by 17.0% year-over-year, from $8.79M to $7.29M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s accounts payable?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s accounts payable has grown at a 29.0% compound annual growth rate (CAGR), from $10.57M to $29.27M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.

Ask your AI about Edgewise Therapeutics, Inc.'s accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude